X
Live / Applied — Fourth extension granted (statement of use) (as of 23 Oct 2025)
What this means for you
Not registered yet, but its 08 Aug 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97539827
- Mark type
- Design + words
- Filed
- 08 Aug 2022
- Published for opposition
- 19 Sept 2023
- Attorney of record
- Christopher M. Hanes
Goods and services
- Class 001 — Chemicals: Oligonucleotide compounds for use in the manufacture of pharmaceutical therapies
- Class 005 — Pharmaceuticals: Oligonucleotide compounds for use as pharmaceutical therapies for the treatment of a wide variety of conditions and illnesses; Oligonucleotide delivery agents that facilitate delivery of a wide range of pharmaceutical therapies; Oligonucleotide-based or -derived pharmaceuticals for the treatment of a wide variety of conditions and illnesses; Pharmaceuticals comprised of oligonucleotide compounds for the treatment of a wide variety of conditions and illnesses ; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals
- Class 040 — Treatment of materials: Custom manufacture of oligonucleotides
- Class 042 — Scientific and technological services: Research and development of oligonucleotide compounds for use in pharmaceutical therapies; Research and development of oligonucleotide delivery agents for use in pharmaceutical therapies; Research and development of oligonucleotide-based or -derived pharmaceuticals; Research and development of pharmaceuticals comprised of oligonucleotide compounds; Research and development of oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents; Research and development of drug delivery agents consisting of oligonucleotide compounds
Owner
- Elsie Biotechnologies Inc., San Diego, CA, US
- Elsie Biotechnologies Inc., San Diego, CA, US
Prosecution history
- 24 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Oct 2025 — SOU EXTENSION 4 GRANTED
- 23 Oct 2025 — SOU EXTENSION 4 FILED
- 23 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 03 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 May 2025 — SOU EXTENSION 3 GRANTED
- 02 May 2025 — SOU EXTENSION 3 FILED
- 02 May 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Dec 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Dec 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 18 Dec 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 11 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Dec 2024 — SOU EXTENSION 2 GRANTED
- 12 Nov 2024 — SOU EXTENSION 2 FILED
- 09 Dec 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL